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Background: POLG1 mutations have been associated with MELAS-like phenotypes. However given several clinical
differences it is unknown whether POLG1 mutations are possible causes of MELAS or give raise to a distinct clinical
and genetic entity, named POLG1-associated encephalopathy.
Case presentation: We describe a 74 years old man carrying POLG1 mutations presenting with strokes, myopathy
and ragged red fibers with some atypical aspects for MELAS such as late onset, lack of cerebral calcification and
presence of frontal and occipital MRI lesions better consistent with the POLG associated-encephalopathy spectrum.
Conclusion: The lack of available data hampers a definite diagnosis in our patient as well as makes it difficult to
compare MELAS, which is a clearly defined clinical syndrome, with POLG1-associated encephalopathy, which is so
far a purely molecularly defined syndrome with a quite heterogeneous clinical picture. However, the present report
contributes to expand the phenotypic spectrum of POLG1 mutations underlining the importance of searching
POLG1 mutations in patients with mitochondrial signs and MELAS like phenotypes but negative for common
mtDNA mutations.
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Mitochondrial myopathy, encephalopathy, lactic acidosis
and stroke-like episodes (MELAS) syndrome is a pheno-
typically and genetically heterogeneous mitochondrial dis-
order. Stroke-like episodes, which are usually transient and
not-disabling, represent the clinical hallmarks. Additional
features include seizures, cognitive decline, psychosis, lactic
acidosis, migraine, visual impairment, hearing loss, short
stature, diabetes and myopathy. MRI shows hyperintensi-
ties on T2-weighted and DWI sequences mostly over the
temporal, parietal and occipital regions, not confined to a
vascular territory. Muscle biopsy typically shows ragged-
red and COX-negative fibers, SDH hyperreactivity and, at
ultrastructural level, abnormally shaped mitochondria with* Correspondence: anna.bersano@gmail.com
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reproduction in any medium, provided the orparacristalline inclusions. MELAS results in 80% of cases
from a point mutation, m.3243A>G in the mitochondrial
tRNALeu(UUR) gene (MTTL1) [1,2]. Other mitochondrial
DNA (mtDNA) mutations in MTTL1 gene and other
transfer RNA genes (MTTF, MTTV, MTTQ) as well as
mutations in other subunits of complex 1 such as MTND1,
MTND5 and MTND6 have been also identified as cause of
MELAS [3-6]. Indeed, mutations in nuclear genes leading
to secondary mtDNA changes (depletions and multiple
deletions), have been described as emerging causes of
MELAS [7]. Recently, Deschauer et al. described a patient
showing stroke-like episodes and a right occipital lesion,
headache, seizures, elevated CSF lactate, ragged–red fibers
and carrying heterozygous mutations in mtDNA polymer-
ase gene (POLG1) arguing that MELAS could be included
in POLG1 spectrum phenotype [7]. POLG1mutations were
described, so far, in families with autosomal dominant and
recessive chronic progressive external ophthalmoplegiaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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late onset ataxia [8,9]. We previously reported a cohort of
67 patients affected by myopathy with or without PEO, in
which 19.4% of patients carried POLG1 mutations [10].
Herein, we report the 2-year neurological follow up of
one of these patients disclosing over time a clinical
phenotype highly consistent with MELAS.
Case presentation
Patient’s history
A 74 year old man was admitted to the Neurological Unit
of Desio Hospital in September 2004 for sudden onset of
a speech disorder and left side weakness. Over the past
ten years he developed a progressive bilateral ptosis, hear-
ing loss and difficulties in swallowing. For these symptoms
he was hospitalized in 1996 elsewhere. The neurological
examination performed at that time revealed bilateral pto-
sis, bilateral hearing loss and mild dysphagia. The neuro-
physiological examination, performed in 1996, revealed a
myopathic pattern. However, at that time the patient
refused any further investigation including muscle biopsy.
The remaining patient’s past history was unremarkable. In
particular, except for a mild increase in cholesterol levels,
cerebrovascular risk factors were absent. Family history
was negative for muscular disorders, stroke, hearing loss,
diabetes, short stature, headache, mental retardation or
dementia. Neurological examination, performed on ad-
mission in 2004, revealed bilateral ptosis and severe
ophthalmoparesis, hearing loss, dysarthria, left facial nerve
palsy and mild left side hemiparesis. Acute phase NIHSS
score was 4. Fatigability and myotonic phenomena were
absent. Acute phase cerebral CT scan was negative for
acute ischemic lesions. Cerebral MRI, performed two days
later, showed a right pre-rolandic hyperintensity on T2-
weighted sequence, not confined to a specific vascular
territory, with a slight enhancement after gadolinium,
consistent with an acute ischaemic lesion. Other bilateral
focal hyperintensities, mostly in the posterior circulation
territory (cerebellar bilateral, left temporo-occipital and
frontal) consistent with stabilized ischaemic lesions, were
also found (Figure 1). Biochemistry was normal except for
increased level of serum creatine kinase (189→643, n.v
38–174 U/l). Inflammatory and autoimmune markers
were normal as well as lactate serum level (1,7; n.v 0.5-
1.8 mmol/l). Electrocardiogram, echocardiography and
abdominal ultrasonography were negative. Audiometry
revealed a moderate sensorimotor bilateral hypoacusia.
Ophthalmological examination, including fluoroangiogra-
phy, excluded a pigmentary retinopathy. Electroencephal-
ography was normal too. Neurophysiological examination
demonstrated myopathic signs in frontal, masseters, orbi-
cularis oculi and mouth muscles without denervation and
normal findings in the other examined muscles (right bi-
ceps, triceps, interosseous and left and right quadriceps,tibialis anterior, medial gemellus). No signs of polyneurop-
athy were detected. Ticlopidine 250 mg twice daily was
started. Left hemiparesis resolved completely within 7
days. During the following years a progressive worsening
of ptosis, ophthalmoparesis, hearing loss and dysphagia
was observed. Cognitive impairment was not detected at
MMSE. Headache and seizures were not referred too. In
November 2008 the patient was hospitalized again for a
sudden onset of aphasia. No other new-onset neurological
symptoms were referred. The neurological examination
performed at that time showed global aphasia and a right
hemiparesis with right Babinski sign. The NIHSS score
was 4. Residual signs such as severe bilateral ptosis, bilat-
eral opthalmoparesis, bilateral hearing loss, dysarthria,
solid food dysphagia were unchanged. Fatigability, cerebel-
lar ataxia or sensitive deficits were absent. Biochemistry,
echocardiography, epiaortic vessel Doppler ultrasound
were normal. Cerebral CT scan performed in the acute
phase was unmodified in comparison to the previous ones.
Cerebral MRI at day 3 demonstrated a small cortical-
subcortical left temporo-occipital lesion with DWI re-
striction (Figure 1). The strength deficit resolved in a few
days whereas a language rehabilitation was necessary.
Aphasia progressively recovered and was not present at
the three months follow-up. The patient continued to as-
sume ticlopidine.
Genetic analysis
Total DNA was extracted from peripheral blood and
muscle. PCR-RFLP analysis did not reveal m.3243A>G
mutation. Southern blot analysis of muscle mtDNA [11]
revealed the presence of several bands compatible with
mtDNA multiple deletions (Figure 2). A specific PCR
assay identified mtDNA multiple deletions using two
primers (forward 7440–7465 and reverse complement
16135–16110) and the following amplification protocol:
an initial denaturation at 94°C for 2 min, followed by 25
cycles (94°C for 30 s, 55°C for 30 s, and 68°C for 90 s)
and a final extension for 2 min at 72°C (Platinum HiFi
Taq Polymerase by Invitrogen, Carlsbad, CA). The entire
coding sequence of POLG1 gene (NM_002693.1) was
PCR-amplified and directly sequenced disclosing the
presence of three heterozygous variants: the c.752C>T
(exon 3, p.T251I), c.1760C>T (exon 10, p.P587L) and
c.3556G>C (exon 22, p.D1186H). We did not test any
other family member for POLG mutations since parents
are not alive and siblings are not available. Both the
mutations p.T251I and p.P587L were reported several
times in subjects showing multiple clinical phenotypes,
according to the Human DNA Polymerase Gamma Muta-
tion Database (http://tools.niehs.nih.gov/polg/). The mis-
sense mutation c.3556G>C was not listed in the dbSNP
database (http://www.ncbi.nlm.nih.gov/projects/SNP/) as
well as in the POLG mutation database and it was not
Figure 1 A-D: Skeletal muscle biopsy showing one ragged red fiber with histological methods (A-B: H&E, 10X ; B: GT, 40X).
Histochemical reactions for COX (C, 10X) and COX-SDH (D, 10X) in cross serial sections show lack of COX activity in several skeletal muscle fibers
(C), many of which also show increased SDH activity (D).E-H: Axial T2-weighted cerebral MRI sequences showing a cortico-subcortical fronto-
parietal hyperintensity with restricted diffusion (not shown) consistent with acute ischaemic lesion and bilateral old ischaemic lesions in the right
occipital and left temporal lobe.
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Figure 2 Molecular analysis of muscle-derived mitochondrial DNA. Southern blot (A) and PCR assay (B) showing the accumulation of
multiple deletions in patient’s tissue.
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affected residue (position 1186) is evolutionarily con-
served across species. Three software programs were used
to predict the overall severity of this variant. According
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT
(Sorting Intolerant From Tolerant, http://sift.bii.a-star.
edu.sg/) and PMut (http://mmb.pcb.ub.es/PMut/), the p.
D1186H change is predicted to be highly deleterious.Skeletal muscle and nerve histopathology
In 2004 the patient underwent a left biceps skeletal
muscle biopsy. Cryostatic cross sections were processed
according to standard histological and histochemical
techniques including Haematoxylin & Eosin (H&E),
Gomori Trichrome (GT), Cytochrome c Oxidase (COX),
Succinate Dehydrogenase (SDH) and double reaction for
COX and SDH [12]. Electron microscopy studies were
performed as described [13].
Histological examination of muscle specimen showed
slight fiber size variability, some nuclear centralizations
and several fiber splittings along with a consistent num-
ber (n=10) of ragged red fibers (RRF). Necrosis was
observed in a few fibers. Histochemically, several fibers
were Cytochrome c Oxidase (COX)-negative, many of
these fibers were also intensely SDH-positive (Figure 1).
DNA sample and muscle biopsy were collected after
obtaining patient informed consent according to the
local ethics and privacy and human subjects’ protection
regulations and were taken as part of standard patient
care.Conclusion
The human mitochondrial genome is replicated by the
DNA polymerase γ, pol γ, which is encoded by POLG1,
which is a 23 exons nuclear gene located on chro-
mosome 15q25. Heterozygous and homozygous POLG1
mutations have been typically associated with heteroge-
neous and severe clinical phenotypes of PEO, both in
autosomal dominant or recessive form. They can also
result in adult onset cerebellar ataxia with mtDNA mul-
tiple deletions and Alpers syndrome, an autosomal re-
cessive hepatocerebral disease characterized by severe
developmental delay, intractable seizures, liver failure
and death in childhood. Moreover, throughout the years
a wide spectrum of clinical findings including parkinson-
ism, neuropathy, optic neuritis, psychiatric disorders has
been described in POLG1 mutations carriers [12,14-19].
Deschauer et al. 2007 described a patient presenting
with occipital seizures and residual homonymous hemi-
anopsia, headache and ataxia and carrying two heterozy-
gous POLG1 mutations [7]. The presence of occipital
symptoms and lesions, interpreted as stroke-like epi-
sodes, together with elevated CSF lactate and ragged red
fibers, posed the suspicion of MELAS, raising the ques-
tion whether POLG1 mutations could be associated with
a MELAS like phenotype [7,20]. However, given several
clinical differences between POLG1 patient characteris-
tics and MELAS, it has been supposed that, despite
some overlapping symptoms, POLG1 represent a distinct
clinical and genetic entity. POLG-associated encephalop-
athy has been postulated to give rise to a distinct pheno-
type, including variable age at onset, either recessive or
dominant inheritance pattern and peculiar neuroimaging
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mic lesions and lack of cerebral calcification [21].
Our case had some atypical aspects for MELAS such
as late onset, lack of cerebral calcification and presence
of frontal and occipital MRI lesions better consistent
with the POLG associated-encephalopathy spectrum.
However, it is difficult to assess with certainty whether
our patient could be classified as MELAS-like or POLG-
associated encephalopathy. Moreover, although the pa-
tient did not present any vascular risk factor, given the
elderly age a co-incidence between a POLG myopathy
and a cerebrovascular disease can not be excluded at all.
However, it is difficult to compare MELAS, which is a
clearly defined clinical syndrome, with POLG1-associated
encephalopathy, which is so far a purely molecularly
defined syndrome with a quite heterogeneous clinical pic-
ture. In addition, although 140 POLG mutations have
been described in patients with symptoms that suggest
mitochondrial disease, most of mutations are reported in
heterozygous in whom each POLG allele can be one or
more different mutations and only few of these has been
replicated in not related families. This makes difficult a
clear definition of phenotype and in providing evidence of
the disease causing nature of these mutations [22].
Our patient harboured the haplotype p.[T251I P587L]
in combination with D1186H located in polymerase do-
main. The haplotype T251I and P587L has been already
described but it is currently not possible to know
whether T251I or P587L is the primary pathogenic allele
or whether both mutations are necessary to cause dis-
ease. Nevertheless both variants have also been reported
in trans one each other in affected subjects. Notably
both P587 and D1186 residues are located in the DNA
binding channel of POLG enzyme. Thus, the substitu-
tions found in our patient could be consistent with a
reduced DNA binding capacity.
However, given the lack of available data, the imple-
mentation of existing databases (http://tools.niehs.nih.gov/
polg/) including single unpublished observations from
clinicians, is necessary to determine allelic frequencies of
the myriad of POLG1 mutations [22,23]. Ongoing studies
on biochemical measurements of polymerase activity and
in vivo measurement of mitochondrial dysfunction will
provide further issue on their pathogenic role.
The present report contributes to expand the pheno-
typic spectrum of POLG1 mutations underlining the im-
portance of searching POLG1 mutations in patients with
mitochondrial signs and MELAS like phenotypes but
negative for common mtDNA mutations.
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